← Back to patent-cliff list
Amifostine for nasoduodenal delivery (Xerient Pharma)
Tier C — Watch / tradeAmifostine for nasoduodenal delivery (Xerient Pharma)
Xerient Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Alkaline phosphatase
Indications (approved)：Pancreatic cancer
Regional status
US
Phase II
2026-01-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amifostine for nasoduodenal delivery (Xerient Pharma)?
Approved indications include: Pancreatic cancer.
When does the Amifostine for nasoduodenal delivery (Xerient Pharma) patent expire?
No public expiry year is available for Amifostine for nasoduodenal delivery (Xerient Pharma) yet; this page updates once verified.
How do I get a quote for Amifostine for nasoduodenal delivery (Xerient Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29